



Amarin Corporation plc  
Investor Relations Department  
2 Pembroke House, Upper  
Pembroke  
Street 28-32  
Dublin 2  
Ireland

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: AMRN**

|               |                            |
|---------------|----------------------------|
| Last Trade:   | 3.07                       |
| Trade Time:   | 3:06 PM ET<br>Apr 19, 2018 |
| Change:       | -0.11  (-3.459%)           |
| Day Range     | 3.06 - 3.21                |
| 52-Week Range | 2.82 - 4.60                |
| Volume        | 2,287,554                  |

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Apr 12, 2018*

[Amarin Sponsors Three Scientific Presentations Scheduled for National Lipid Association Scientific Sessions](#)

*Apr 12, 2018*

[Vascepa® \(Icosapent Ethyl\) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin-Treated Patients with Reduced Kidney Function and Persistent High Triglycerides](#)

*Apr 4, 2018*

[Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT Cardiovascular Outcomes Study Progress and Vascepa® Promotion Initiatives](#)

*Apr 4, 2018*

[Amarin's REDUCE-IT Cardiovascular Outcomes Study Reaches 100% Mark for Estimated Onset of Target Primary Major Adverse Cardiovascular Events](#)

*Mar 29, 2018*

[Amarin Sponsors Two Scientific Presentations Scheduled for National Kidney Foundation 2018 Spring Clinical Meetings](#)

## Financials [\[ View all \]](#)

[Fourth Quarter Financial Results](#)

*Feb 27, 2018*

[Annual Report \(10-K\)](#)

*Apr 21, 2017*

[Proxy Statement \(DEF 14A\)](#)

*Nov 1, 2017*

[Quarterly Report \(10-Q\)](#)

*Aug 2, 2017*

[Quarterly Report \(10-Q\)](#)

*May 3, 2017*

[Quarterly Report \(10-Q\)](#)